Samara Y, Aldoss I. Refining post-blinatumomab risk stratification through ultrasensitive-based measurable residual disease assessment. haematol [Internet]. 2020Sep.10 [cited 2026Apr.19];. Available from: https://haematologica.org/article/view/14133